LIGHTPATH TECHNOLOGIES INC
Business
LightPath Technologies Inc designs, manufactures and supplies optical and photonics products and integrated imaging subsystems and systems. It offers infrared and visible optical components, precision molded aspheric lenses, proprietary BlackDiamond glass materials, optical coatings, optical assemblies, camera modules and engineering/design services for thermal imaging, night vision and IoT applications. The company operates through four product groups—infrared components, visible components, assemblies and modules, and engineering services—and via subsidiaries including ISP, Visimid and G5 Infrared. It sells globally to defense, public safety, industrial, commercial, telecom and medical customers via direct sales, OEM channels and trade shows, with manufacturing in the U.S., China and Latvia.
Summary from filing dated 2025-09-26
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Revenue, net | 37 | 32 | 33 | 36 | 38 | |
| Cost of sales | 27 | 23 | 22 | 24 | 25 | |
| Gross profit | 10 | 9 | 11 | 12 | 13 | |
| Selling, general and administrative | 16 | 12 | 11 | 11 | 12 | |
| New product development | 3 | 2 | 2 | 2 | 2 | |
| Amortization of intangible assets | 1 | 2 | 1 | 1 | 1 | |
| Change in fair value of acquisition liabilities | 2 | 0 | — | — | — | |
| Loss on disposal of property and equipment | 99,334 | 124,584 | — | 9,235 | 8,951 | |
| Total operating expenses | 22 | 16 | 15 | 14 | 15 | |
| Operating loss | −12 | −8 | −4 | −3 | −2 | |
| Interest expense, net | −1 | −191,862 | −283,266 | −229,475 | −215,354 | |
| Loss on extinguishment of debt | −418,502 | 0 | — | — | — | |
| Change in fair value of warrant liability | −1 | 0 | — | — | — | |
| Other income (expense), net | −122,080 | 78,670 | −258,296 | −52,040 | −409,524 | |
| Total other income (expense), net | −3 | −113,192 | — | — | −409,524 | |
| Loss before income taxes | −15 | −8 | — | — | −2 | |
| Income tax provision | 37,790 | 67,490 | 234,034 | 862,907 | 933,915 | |
| Net loss | −15 | −8 | −4 | −4 | −3 | |
| Foreign currency translation adjustment | 468,750 | −96,600 | −328,589 | −1 | — | |
| Comprehensive loss | −14 | −8 | −4 | −5 | −2 | |
| Loss per common share (basic) | −0.36 | −0.21 | −0.13 | −0.13 | −0.12 | |
| Number of shares used in per share calculation (basic) | 41 | 38 | 32 | 27 | 26 | |
| Loss per common share (diluted) | −0.36 | −0.21 | −0.13 | −0.13 | −0.12 | |
| Number of shares used in per share calculation (diluted) | 41 | 38 | — | 27 | 26 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 5 | 3 | 7 | — | — | |
| Trade accounts receivable, net of allowance of $24,495 and $25,676 | 9 | 5 | 7 | — | 5 | |
| Inventories, net | 13 | 7 | 7 | 7 | 9 | |
| Prepaid expenses and deposits | 1 | 445,900 | 570,293 | 464,804 | 475,364 | |
| Other current assets | 40,150 | 131,177 | 0 | — | — | |
| Total current assets | 28 | 16 | 22 | 18 | 21 | |
| Property and equipment, net | 16 | 15 | 13 | 12 | 13 | |
| Operating lease right-of-use assets | 7 | 7 | 10 | 10 | 9 | |
| Intangible assets, net | 16 | 4 | 3 | 4 | 6 | |
| Goodwill | 14 | 7 | 6 | 6 | 6 | |
| Deferred tax assets, net | 22,571 | 123,000 | — | 143,000 | 147,000 | |
| Other assets | 73,917 | 59,602 | 65,939 | — | 27,737 | |
| Total assets | 82 | 48 | 54 | 51 | 55 | |
| Accounts payable | 7 | 3 | 3 | 3 | 3 | |
| Accrued liabilities | 6 | 2 | 662,242 | 558,750 | 1 | |
| Accrued payroll and benefits | 2 | 1 | 1 | 2 | 3 | |
| Operating lease liabilities, current | 1 | 1 | 969,890 | 965,622 | 799,507 | |
| Loans payable, current portion | 172,567 | 209,170 | 1 | 998,692 | 634,846 | |
| Finance lease obligation, current portion | 206,518 | 177,148 | 103,646 | 55,348 | 212,212 | |
| Total current liabilities | 17 | 8 | 7 | 8 | 8 | |
| Deferred tax liabilities, net | 152,760 | 326,197 | 465,000 | 541,015 | 0 | |
| Accrued liabilities, noncurrent | 823,000 | 611,619 | 0 | — | — | |
| Finance lease obligation, less current portion | 421,363 | 528,753 | 341,201 | 11,454 | 66,801 | |
| Operating lease liabilities, noncurrent | 8 | 8 | 8 | 9 | 8 | |
| Loans payable, less current portion | 5 | 325,880 | 2 | 3 | 4 | |
| Total liabilities | 32 | 18 | 18 | 21 | 21 | |
| Series G Convertible Preferred Stock; $0.01 par value; 44,000 shares authorized; 24,956 shares issued and outstanding | 34 | 0 | — | — | — | |
| Preferred stock: Series D, $.01 par value, voting; 500,000 shares authorized; none issued and outstanding | 0 | 0 | 0 | 0 | 0 | |
| Common stock: Class A, $.01 par value, voting; 94,500,000 shares authorized; 42,949,307 and 39,254,643 shares issued and outstanding | 429,493 | 392,546 | 373,447 | 270,468 | 269,859 | |
| Additional paid-in capital | 245 | 245 | 243 | 232 | — | |
| Accumulated other comprehensive income | 978,686 | 509,936 | 606,536 | 935,125 | 2 | |
| Accumulated deficit | −231 | −216 | −208 | −204 | −200 | |
| Total stockholders' equity | 16 | 30 | 36 | 30 | 34 | |
| Total liabilities, convertible preferred stock and stockholders' equity | 82 | 48 | 54 | 51 | 55 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Net loss | −15 | −8 | −4 | −4 | −3 | |
| Depreciation and amortization | 4 | 4 | 3 | 4 | 4 | |
| Interest from amortization of loan issuance costs | 213,829 | 0 | 58,774 | 51,974 | 18,572 | |
| Amortization of fair value of loan | 71,215 | 0 | — | — | — | |
| Change in fair value of warrant liability | 1 | 0 | — | — | — | |
| Change in fair value of acquisition earnout liabilities | 2 | 0 | — | — | — | |
| Loss on disposal of property and equipment | 94,860 | 124,584 | — | — | — | |
| Stock-based compensation on stock options, RSUs & RSAs, net | 1 | 1 | — | 825,250 | 642,865 | |
| Provision for credit losses | −3,014 | −4,426 | 8,158 | 7,713 | −35,799 | |
| Change in operating lease assets and liabilities | −273,624 | 183,393 | −231,561 | −222,047 | — | |
| Inventory write-offs to allowance | 143,362 | 136,676 | 316,297 | 456,538 | 157,399 | |
| Deferred taxes | −221,977 | −121,803 | −73,015 | 545,015 | — | |
| Trade accounts receivable | −3 | 1 | −1 | −562,651 | 2 | |
| Other current assets | 91,027 | −131,177 | 0 | — | — | |
| Inventories | −1 | 960,739 | −741,604 | 1 | 167,496 | |
| Prepaid expenses and deposits | −325,915 | 133,810 | −97,792 | 10,560 | 137,810 | |
| Accounts payable and accrued liabilities | 2 | 680,457 | −977,622 | −1 | 1 | |
| Net cash (used in) provided by operating activities | −8 | 521,037 | −3 | 1 | 5 | |
| Purchase of property and equipment | −1 | −2 | −3 | −2 | −3 | |
| Proceeds from sale of equipment | 10,648 | 0 | 209,169 | 0 | 0 | |
| Proceeds from sale-leaseback of equipment | 0 | 364,710 | — | — | — | |
| Acquisition of G5 | −18 | 0 | — | — | — | |
| Acquisition of Visimid, net of cash acquired | 0 | −847,141 | — | — | — | |
| Net cash used in investing activities | −20 | −3 | −3 | −2 | −3 | |
| Proceeds from exercise of stock options | 3,175 | 0 | — | 0 | 142,692 | |
| Proceeds from sale of common stock from Employee Stock Purchase Plan | 14,385 | 39,677 | — | — | — | |
| Proceeds from issuance of common stock under public equity placement | 0 | 806,332 | — | — | — | |
| Proceeds from issuance of common stock under private equity placement, net of fees | 437,725 | 0 | 9 | 0 | — | |
| Proceeds from issuance of preferred stock under private equity placement, net of fees | 19 | 0 | — | — | — | |
| Proceeds from issuance of warrants under private equity placement | 5 | 0 | — | — | — | |
| Deferred payment for acquisition of Visimid | −125,000 | 0 | — | — | — | |
| Borrowings on loans payable | 7 | 278,926 | 141,245 | 266,850 | — | |
| Loan issuance costs | −597,465 | 0 | — | — | — | |
| Payments on loans payable | −204,100 | −2 | — | — | — | |
| Repayment of finance lease obligations | −187,626 | −131,901 | −73,003 | −212,211 | −278,462 | |
| Net cash provided by (used in) financing activities | 29 | −1 | 7 | −636,174 | −843,429 | |
| Effect of exchange rate on cash and cash equivalents | 170,204 | −53,583 | −141,769 | −468,143 | 657,495 | |
| Change in cash, cash equivalents and restricted cash | 1 | −4 | 2 | −1 | 1 | |
| Interest paid in cash | 273,476 | 196,541 | 221,773 | 157,407 | 199,524 | |
| Income taxes paid | 206,121 | 166,858 | 428,914 | 267,585 | 1 | |
| Purchase of equipment through finance lease arrangements | 93,048 | 396,058 | 451,048 | 0 | — | |
| Operating right-of-use assets acquired in exchange for operating lease liabilities | 0 | 92,136 | 0 | — | — | |
| Issuance of common stock for acquisition of Visimid | 713,946 | 486,054 | — | — | — | |
| Issuance of common stock for acquisition of G5 | 5 | 0 | — | — | — | |
| Accrual of earnout consideration for acquisition of G5 | 4 | 0 | — | — | — | |
| Extinguishment of debt in exchange for common stock, preferred stock, warrants and a note | 3 | 0 | — | — | — |